AbbVie Inc. $ABBV Shares Sold by Arlington Trust Co LLC

Key Points

• Arlington Trust Co LLC reduced its position in AbbVie by 90.8% in Q4, selling 5,249 shares and leaving 530 shares valued at about $121,000.
• AbbVie’s pipeline shows mixed signals: it submitted an FDA application to expand SKYRIZI for Crohn’s disease (potential upside), but has recent FDA rejections/CRLs for other products and faces competitive threats that could delay launches.
• Analysts maintain a consensus “Moderate Buy” with an average price target of $253.19 versus the ~$197 share price; the company recently beat quarterly EPS/revenue, set FY2026 guidance, and pays a $1.73 quarterly dividend (3.5% yield).

Arlington Trust Co LLC reduced its position in shares of AbbVie Inc. (NYSE:ABBV - Free Report) by 90.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 530 shares of the company's stock after selling 5,249 shares during the period. Arlington Trust Co LLC's holdings in AbbVie were worth $121,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Chelsea Counsel Co. acquired a new position in shares of AbbVie during the third quarter worth $26,000. Westend Capital Management LLC acquired a new position in shares of AbbVie during the fourth quarter worth $29,000. Texas Capital Bancshares Inc TX acquired a new position in shares of AbbVie during the third quarter worth $31,000. WestEnd Advisors LLC lifted its position in shares of AbbVie by 160.4% during the fourth quarter. WestEnd Advisors LLC now owns 138 shares of the company's stock worth $32,000 after purchasing an additional 85 shares in the last quarter. Finally, Caitlin John LLC acquired a new stake in AbbVie in the third quarter valued at $33,000. 70.23% of the stock is owned by institutional investors and hedge funds.

Key Headlines Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Submitted FDA application to expand SKYRIZI (risankizumab-rzaa) to a subcutaneous induction option for adults with moderately to severely active Crohn’s disease — could broaden an already approved label and support future sales growth for Risankizumab. AbbVie Submits Regulatory Application to FDA for SKYRIZI® (risankizumab-rzaa) Subcutaneous Induction
• Positive Sentiment: Plans for a $1B+ research campus in the Raleigh‑Durham life‑sciences hub — signals long‑term investment in R&D footprint and improves access to talent/partnerships in a growth market. AbbVie's Planned $1B-Plus Research Triangle Campus Development Buoys Improved Life Sciences Outlook
• Positive Sentiment: Analyst/commentary pieces highlight AbbVie’s strong dividend profile and cash flow driven by core drugs — supports investor income thesis and lowers perceived downside for income‑focused holders. AbbVie (ABBV) Maintains Dividend Strength as Core Drugs Drive Cash Flow
• Neutral Sentiment: Q1 earnings are due imminently and previews show analysts watching drug demand and margins — results/guidance will likely drive near‑term moves more than stale news. AbbVie (ABBV) to report earnings tomorrow: Here is what to expect
• Negative Sentiment: FDA rejected AbbVie’s wrinkle‑treatment application due to manufacturing issues — raises short‑term regulatory and manufacturing execution concerns. FDA rejects AbbVie wrinkle treatment application over manufacturing issues
• Negative Sentiment: AbbVie received a Complete Response Letter (CRL) from the FDA for trenibotulinumtoxinE — another regulatory setback that could delay a product launch and near‑term revenue upside. AbbVie Inc. (ABBV) Receives CRL from the FDA About the Biologics License Application for trenibotulinumtoxinE
• Negative Sentiment: Small biotech Oruka reported strong psoriasis results that investors view as a potential threat to AbbVie’s large dermatology franchise — increased competition could pressure long‑term growth assumptions for that business. How A Small Biotech Name Just Rattled AbbVie's $18 Billion Franchise

Analysts Set New Price Targets

Several analysts recently issued reports on ABBV shares. UBS Group cut their price target on shares of AbbVie from $240.00 to $230.00 and set a "neutral" rating on the stock in a report on Thursday, February 5th. The Goldman Sachs Group reaffirmed a "neutral" rating and issued a $223.00 price target on shares of AbbVie in a report on Wednesday, January 28th. Weiss Ratings reaffirmed a "hold (c)" rating on shares of AbbVie in a report on Wednesday, January 21st. Sanford C. Bernstein reaffirmed a "market perform" rating on shares of AbbVie in a report on Thursday, February 5th. Finally, Barclays started coverage on shares of AbbVie in a report on Thursday, February 19th. They issued an "overweight" rating and a $275.00 price target on the stock. Three research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $253.19.

AbbVie Stock Performance

Shares of NYSE:ABBV opened at $197.24 on Tuesday. The stock has a market capitalization of $348.76 billion, a price-to-earnings ratio of 83.58, a price-to-earnings-growth ratio of 0.71 and a beta of 0.38. AbbVie Inc. has a 1-year low of $176.57 and a 1-year high of $244.81. The company's fifty day moving average is $215.99 and its two-hundred day moving average is $222.03.

AbbVie (NYSE:ABBV - Get Free Report) last issued its earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share for the quarter, topping analysts' consensus estimates of $2.65 by $0.06. The company had revenue of $16.62 billion for the quarter, compared to analysts' expectations of $16.39 billion. AbbVie had a net margin of 6.91% and a negative return on equity of 1,579.75%. The firm's revenue was up 10.0% compared to the same quarter last year. During the same period in the prior year, the company earned $2.16 earnings per share. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. Sell-side analysts expect that AbbVie Inc. will post 14.21 EPS for the current fiscal year.

AbbVie Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be issued a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.5%. The ex-dividend date of this dividend is Wednesday, April 15th. AbbVie's dividend payout ratio is 293.22%.

Insiders Place Their Bets

In other AbbVie news, SVP David Ryan Purdue sold 5,230 shares of the stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $233.56, for a total transaction of $1,221,518.80. Following the sale, the senior vice president directly owned 2,654 shares of the company's stock, valued at approximately $619,868.24. This represents a 66.34% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Perry C. Siatis sold 22,381 shares of the stock in a transaction on Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the sale, the executive vice president directly owned 38,137 shares in the company, valued at $8,771,510. This trade represents a 36.98% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 0.06% of the stock is currently owned by corporate insiders.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.

Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.